Source comparison
TB-500 vs BPC-157: Half-Life Comparison
TB-500 10–12 hours 30–60 minutes post-injection 2–3 times per week 5–7 days (tissue repair cascade) Longer plasma half-life but similar therapeutic window to BPC-157 due to downstream signaling BPC-157 4 hours 15–30 minutes post-injection 1–2 times per day 3–5
This comparison does not assign a generated winner or score.
- TB-500
- 10–12 hours
- 30–60 minutes post-injection
- 2–3 times per week
- 5–7 days (tissue repair cascade)
- Longer plasma half-life but similar therapeutic window to BPC-157 due to downstream signaling
- BPC-157
- 4 hours
- 15–30 minutes post-injection
- 1–2 times per day
- 3–5 days (angiogenesis and ECM remodeling)
- Shorter plasma half-life requires more frequent dosing, but depot formation at injection site extends local effect
- Combined Protocol
- Variable (staggered dosing)
- Depends on timing
- TB-500 twice weekly + BPC-157 daily
- Overlapping repair mechanisms
- Complementary pathways. TB-500 drives actin-mediated migration, BPC-157 accelerates angiogenesis via VEGF
- The comparison clarifies why TB-500 is dosed less frequently than BPC-157 despite both having short plasma clearance times. TB-500's effect is systemic and structural; BPC-157's is localized and vascular. Our research institutions often stack both peptides in protocols targeting complex soft tissue injuries.